EU Advocate General Sides With Pfizer Over Orifarm’s Parallel Importing Of Enbrel
Executive Summary
An advocate general of the Court of Justice of the EU has given an opinion in the case of Pfizer v Orifarm that, if followed by the full court, will clarify the scope of the “specific mechanism” that was introduced to give patent holders protection against parallel imports from the acceding member states between 2004 and 2013.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.